Clostridioides difficile infection (CDI) is one of the major issues in nosocomial infections.
This bacterium is constantly evolving and poses complex challenges for clinicians, often …

Background: Clostridioides difficile infection (CDI) is associated with substantial morbidity
and mortality as well as high propensity of recurrence. Systemic antibiotic therapy (SAT) …

Objectives Clostridioides difficile infection (CDI) is one of the leading nosocomial infections
worldwide, resulting in a significantly increasing burden on the healthcare systems …

Background A toxoid-based Clostridioides difficile vaccine is currently in development. Here,
we report lot-to-lot consistency, immunogenicity, safety, and tolerability of 3 C difficile …

Antibiotics are modifiable risk factors for Clostridioides difficile infection (CDI), driving
pathogenesis via gut microbiome disruption. The management of patients with CDI …

Clostridioides difficile causes a range of debilitating intestinal symptoms that may be fatal. It
is particularly problematic as a hospital-acquired infection, causing significant costs to the …

Clostridioides difficile infection (CDI) is a life-threatening disease caused by the Gram-
positive, opportunistic intestinal pathogen C. difficile. Despite the availability of antimicrobial …

Clostridioides difficile colonizes a polymicrobial environment in the intestine and is a
causative agent for antibiotic-associated diarrhea (AAD) and pseudomembranous colitis …

In spite of the widespread implementation of preventive strategies, the prevalence of
healthcare-associated infections (HAIs) remains high. The prevalence of multidrug resistant …

Fecal communities transplanted into individuals can eliminate recurrent Clostridioides
difficile infection (CDI) with high efficacy. However, this treatment is only used once CDI …